The Global Atopic Dermatitis Drugs market is growing at 4.66% of CAGR over the forecasting years. Growing
incidences of allergies due to particular
foods is the major factor augmenting the market growth globally.
MARKET
INSIGHTS
Atopic Dermatitis is a skin
disease also known as chronic eczematous. The symptoms of this disease vary
person to person. However, some of its
common symptoms are inflamed and itchy skin that causes crackling, minute
blisters, swelling, scaling, and crusting. The global Atopic Dermatitis drugs
market comprise of two segments route of administration and drug class. The
topical segment holds the highest share in the Atopic Dermatitis Drugs route of
administration market. The interleukin inhibitor segment is anticipated to
generate the highest revenue in the
Atopic Dermatitis drug class market. The global Atopic Dermatitis Drugs market
is highly generic which creates a lot of challenges in the growth of the market
globally.
REGIONAL
INSIGHTS
The Atopic Dermatitis Drugs
market is segmented in four key
geographies like North America, Europe, Asia Pacific, and rest of world. NorthAmerica is the global leader in the Atopic Dermatitis Drugs market. Growing
allergies is the key reasons for the growth of this market in the North American region. Europe Atopic DermatitisDrugs market continues to escalate in terms of
revenue majorly due to the rising awareness among the population. Atopic Dermatitis
is highly prevalent in APAC region. It is the second largest Atopic Dermatitis
Drugs market during the forecasting years. It is also the most common skin
disease in the region, so the demand for the
market is highest in APAC region.
COMPETITIVE
INSIGHTS
The
established players in the market are Allergan Plc., Aqua Pharmaceuticals (An
Almirall Company), Astellas Pharma Inc., Bayer Ag, Biofrontera Ag,
Bristol-Myers Squibb, Stiefel Laboratories Inc., Encore Dermatology, Galderma
Sa, Leo Pharma, Meda Pharmaceuticals (Mylan), Novartis Ag, Pfizer, Regeneron
Pharmaceuticals, Sanofi Sa, and Valent Pharmaceutical Inc.
Geographically, the Atopic Dermatitis Drugs market has been segmented on the basis of four major regions, which include:
Atopic Dermatitis Drugs North America Market – United States, & Canada
Atopic Dermatitis Drugs Europe Market – Germany, France, United Kingdom, Russia and Rest of Europe
Atopic Dermatitis Drugs Asia-Pacific Market – India, China, Japan, Australia, South Korea & Rest of APAC
Comments
Post a Comment